Octreotide0 vendors competing
No vendor pricing available for this peptide yet.
Research details
Octreotide — research data
Regulatory statusFDA-approved (Sandostatin)
NCAA D1Not listed
Overview
About Octreotide
Mechanism of action
Somatostatin receptor agonist (SSTR2/5); inhibits GH, IGF-1, insulin, glucagon secretion
Safety profile
GI disturbances, cholelithiasis, bradycardia, hyperglycemia · Decades of use; gallstones, GI side effects, glucose changes manageable; well-characterized
Related pages